Last year’s vaccine sales decline hurt Moderna’s stock (MRNA), making it one of the worst performers in the S&P 500 in 2023. The weekly chart below will give you a bird’s eye view of how…
Stocks
-
-
In this edition of StockCharts TV‘s The Final Bar, guest Mish Schneider of MarketGauge talks strength in small caps, leadership in retail, and the importance of watching junk bonds for risk-on conditions. Dave charts pullbacks in AAPL…
-
I’m sure most of you, by now, know that I’m a student of history. 2023 played out beautifully and mostly according to its historical road map. Here are a couple things in 2023, with respect…
-
The equity markets have ended the year on a very strong note. As the week comes to a close, we not only end the month but also the year. On a monthly basis, the Nifty…
-
Happy New Year! Throughout 2024, I’ll be commenting on various sectors, industry groups, and individual stocks that flash breakouts and relative strength, but what about stocks that are just beginning to strengthen? There are many…
-
In this edition of the GoNoGo Charts show, as the S&P 500 continues trading at all-time highs on this final trading day of the year, Alex and Tyler take a look at GoNoGo Trend® conditions…
-
In this special all-Mailbag edition of StockCharts TV‘s The Final Bar, Dave answers viewers’ burning questions, ranging from the effectiveness of short-term moves with the 5-day MA to deciphering the mysteries of the Russell 2000’s growth or…
-
In this episode of StockCharts TV‘s The MEM Edge, join Mary Ellen as she as she dives into the latest news and trends that are driving price action in the markets. From housing updates to consumer confidence…
-
On this week’s edition of Moxie Indicator Minutes, TG points out how broadly supported the market has been this time around, and how he’s seeing excellent setups on the higher time frames. He walks us…
-
For the new year, we have given you an extensive 3-pronged look at the markets. First, we have the general outlook for the economy and markets through the Outlook 2024. This is the general outlook…